SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Celgene-CELG
An SI Board Since August 1996
Posts SubjectMarks Bans Symbol
804 71 0 CELG
Emcee:  rkrw Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
754Merrill 2Q08 beats on strong Revlimid, Thalomid, Vidaza sales 2Q08 EPS, ex-itemtom pope-7/24/2008
753Wow, gotta say I'm a bit surprised, and if MOGN hadn't been taken out, Ituck-7/1/2008
752Dacogen failed to show a statsig advantage on median survival in phase III: theidos-7/1/2008
751May 09 Company Ticker Brokerage Firm Ratings Change Price Target Celgene CELGDoc Bones-5/9/2008
750No generic company has yet found its way around the S.T.E.P.S. patents, but the idos-3/28/2008
749Barr licensed CELG S.T.E.P.S. patents for some other candidate, so it is not cleMiljenko Zuanic-3/28/2008
748My feeling is that the JNK inhibitors are effectively dead. For proof, see link former_pgs-3/27/2008
747Ah, thanks, got the latest Reader and that did the trick. Well . . . tuck-3/27/2008
746You're right, Thalomid's exclusivity is not protected by COM patents (itidos-3/27/2008
745I think Barr's ANDA will succeed if they succeed in court -- I think Barr hatuck-3/27/2008
744What is your prediction for Barr's generic Thalidomide NDA?Miljenko Zuanic-3/27/2008
743>>Vidaza currently splits the US market in the treatment of MDS with Dacogtuck-3/27/2008
742Merrill Revlimid NDC data tracking in-line to modestly ahead Over the past few tom pope-3/27/2008
741From Bane to Blockbuster [Barrons] By LESLIE P. NORTON MONDAY, FEBRUARY 25, 200Doc Bones-2/25/2008
740>>application is currently under review at the EMEA for Revlimid in the trtuck-1/24/2008
739Revlimid Boosts Celgene Revenue By Elizabeth Trotta Staff Reporter 1/7/2008 9:1Doc Bones-1/7/2008
738Celgene Corporation Reviews 2007 Achievements and Announces 2008 Financial Outlosim1-1/7/2008
737Merrill's view gibes with Citi's: notablecalls.blogspot.com CELG reportuck-1/3/2008
736Merrill - maintain buy CELG stock down but estimates and thesis intact CELG stotom pope-12/12/2007
735<b>Celgene's Revlimid delays myeloma progression</b> reuters.coidos-12/10/2007
734Celgene to Acquire Pharmion for $2.9 Billion in Cash and Stock Sunday November 1sim1-11/18/2007
733Cramer: Why Celgene Makes Sense Jim Cramer interviews Adam Feuerstein on CelgeneDoc Bones-9/26/2007
732[Lenalidomide in Myeloma/induction therapy] >>Curr Treat Options Oncol. 2tuck-8/24/2007
731>>Celgene Reports Record Second Quarter Product Sales and Operating Profittuck-8/20/2007
730ML- I bought a few today: Revlimid approved in EU for multiple myeloma As expectom pope-6/19/2007
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News